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cords. The diabetes related complications considered in this study were classified
into chronic complications (Cardiovascular disease, Cerebrovascular disease, Neu-
ropathy, Retinopathy, Nephropathy, Peripheral vascular diseases and foot damage)
and acute complications (Ketoacidosis and major hypoglycemic). The direct med-
ical costs were reported as annual costs including hospitalization, daily medica-
tions and examinations for DM-related chronic complications and as event costs
for DM-related acute ones. All costs were reported in 2011 US dollar using the
exchange rate of 6.47 Chinese Yuan to 1 USD. RESULTS: The annual medical cost
for DM related complications per patient with and without hospitalizations: Myo-
cardial infarction $6248.32 and $2025.26; Angina $4707.12 and $1453.63; Congestive
Heart Failure $3433.08 and $1009.18; Stroke $3214.74 and $1401.46; Peripheral vas-
cular disease $3348.11 and $1301.34; Neuropathy $2226.86 and $854.38. Renal fail-
ure with Haemodialysis $11245.93 and Peritoneal dialysis $7802.03; Renal trans-
plant $33772.50 with operation and $8934.27 for daily maintenance. The event cost
for Retinopathy: Laser operation $296.79; Cataract operation $1313.56; Amputation
$2072.22; Infected ulcer treatment: $3007.11; Ketoacidosis $1493.55; Major hypogly-
cemic $729.18. CONCLUSIONS: Themedical costs for DM related complications are
overwhelming compared with the costs of insulin and hypoglycemic agents espe-
cially for those diabetic patients with severe nephropathy. Considering the high
prevalence of diabetes and its complications diabetes poses substantial economic
burden to the whole society in China.
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OBJECTIVES: The primary objective of this study was to estimate the cost effec-
tiveness of treating diabetic foot ulcers with ANGIPARS™ plus good wound care
(GWC) compared with GWC alone in Iranian health care settings. A secondary
objective was to analyse the effect of different treatment practices on the econom-
ics of caring for diabetic foot ulcers.METHODS: A 6-month Markov computer sim-
ulation model was used to assess the cost effectiveness in Iran of treating diabetic
foot ulcers with ANGIPARS™ plus GWC versus GWC alone. Transition probabilities
were taken from a prospective study of 20 patients and ANGIPARS™ efficacy was
based on 20-week healing rates in a recentmeta-analysis of clinical trials involving
50 patients. Country-specific treatment cost data were collected in collaboration
with local economic consultations and combined with the disease model to esti-
mate the incremental cost per ulcer-free month gained. The model was then run
using hypothetical low- and high-intensity resource usage profiles to investigate
the economics of caring for diabetic foot ulcers. RESULTS: Over the course of
6-month, individuals who received ANGIPARS™ plus GWC were, on average, pre-
dicted to spend an additional 0.81 months (24% longer) free of ulcers and to expe-
rience a 9% lower risk of undergoing a lower extremity amputation than individu-
als who received GWC alone. Consequently, ANGIPARS™ plus GWCwas estimated
to be net cost saving in Iran. CONCLUSIONS: ANGIPARS™ may be a cost-effective
treatment for neuropathic diabetic foot ulcers in a wide range of Iranian settings.
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OBJECTIVES: The diabetic peripheral neuropathy (DPN) is the most common dia-
betic patients’ complicationwhich is accompaniedwith substantial economic bur-
den regarding the productivity loss andmedical therapy. In this studywe analyzed
the cost effectiveness of pregabalin for treatment of diabetic neuropathic pain in
Iran. METHODS: To evaluate the efficacy of pregabalin we designed a systematic
review of published articles by searching on PubMed, Scopus and Google scholar.
Our keywords were: “pregabalin”, “neuropathic pain”, “diabetic peripheral neurop-
athy”, etc. The pain score was the outcome of interest for evaluation of the treat-
ment efficacy in peripheral neuropathic pain. For calculation of cost we only con-
sider direct cost of treatment. RESULTS:Out of 8994, finally 5 articleswere included
in the studywhichmet our inclusion criteria. All of these reportswere Randomized
Clinical Trial (RCT) of the comparison of pregabalin with placebo. Considering the
efficacy extracted from the reports, pregabalin 75 mg/day and 150 mg/day didn’t
have any significant efficacy in comparison with placebo thus the ICER for other
treatment doses was calculated. In pregabalin 300 mg/day the ICER for domestic
produced generic pregabalin was 0.27 dollar per day per pain score reduction and
for imported Lyrica was 2.74 dollar per day per pain score reduction. The results for
pregabalin 600 mg/day were 0.62 and 4.37 respectively. CONCLUSIONS: Our anal-
ysis indicated pregabalin 300 mg/day and 600 mg/day as cost effective treatments.
About the inclusion of pregabalin into insurance positive list if the prescribers
prefer to order pregabalin once a day (As we learned from the expert opinion)
therefore only 300 mg and 600 mg dosage forms are eligible for including into the
positive list.
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OBJECTIVES: To assess medical literature for an overview of the cost-effectiveness
of second-line treatment strategies to achieve different target levels of HbA1c in
subgroups of type 2 diabetes patients.METHODS: Studies are being retrieved from
Pubmed, Cochrane and HEED databases using relevant search strategies. Pre-spec-
ified inclusion/exclusion criteria will identify study types, such as randomized
controlled trials (RCTs), observational and retrospective studies assessing the role
of HbA1c targets in glycaemic control of type 2 diabetes patients. The outcomes of
interest are HbA1c, blood glucose levels, treatment, hypoglycaemia, adherence to
therapy and economic and clinical consequences of therapy. Two researchers are
independently extracting the data from included studies. Clinical data from RCTs
will be analysed using RevMan (5). RESULTS: Though there have been several trials
assessing glycaemic control in type 2 diabetes in the last few years, the wealth of
new evidence is useful but confusing and conflicting. This study will probably
provide the much-needed evidence for glycaemic goal in different groups of type 2
diabetes patients. The study hopes to demonstrate whether there would be glycae-
mia-independent differences in HbA1c between ethnic groups and the evidence of
time dependency of HbA1c. CONCLUSIONS: The data from published studies will
hopefully answer some of the prevailing uncertainties regardingHbA1c targets and
inform policy makers and health professionals about the existing evidence in the
treatment of type 2 diabetes.
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OBJECTIVES: Over a decade ago, Briggs and O’Brien declared the ‘death’ of cost-
minimisation analysis (CMA). The principle of CMA, however, as described by
Drummond is still being considered valid by regulators such as the Australian
Pharmaceutical Benefits Advisory Committee (PBAC), which recommends which
drugs should be reimbursed under the Pharmaceutical Benefits Schedule (PBS).
This study sought to examine the evidence needed for drug reimbursement in
Australia for diabetes drugs when presenting a CMA. METHODS: Current PBAC
guidelines were reviewed specifically from a cost minimisation point of view. Pub-
lic summary documents (which summarise PBAC deliberations) for all reimburse-
ment decisions related to diabetes drugs over the past 5 years were extracted. Data
pertaining to clinical claims, economic analyses and decision were analysed.
RESULTS: Public summary documents were reviewed for eight diabetes drugs:
insulin glulisine, insulin detemir, liraglutide pioglitazone, rosiglitazone, saxaglip-
tin, sitagliptin, vildagliptin. Of these, five reimbursement submissions were based
on CMAs, two on cost effectiveness analyses (CEA) and one on both. The CMA
submissions demonstrated non-inferioritywhen compared to the nominated com-
parator either by presenting head-to-head clinical trial evidence, adjusted indirect
comparisons or pooled individual patient data (IPD) analyses. All were recom-
mended for reimbursement in Australia. Notably, budget impact of each was lim-
ited (AU$10 million over a 5-year period). The three CEA submissions claimed
superiority of their products over the nominated comparators either in terms of
efficacy or safety but none were successful. Notably, each was associated with a
considerable budget impact. CONCLUSIONS: Far from being dead, CMA remains
alive and well in Australia. The PBAC accepts CMAs on the basis of non-inferiority
and perhaps also if reimbursement is associated with a limited budget impact.
Acceptable evidence is not restricted to head-to-head trials, but also includes ad-
justed indirect comparisons as well as IPD pooled from multiple clinical trials.
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OBJECTIVES: To evaluate the long-term cost-utility of liraglutide versus
glimepiride as add-on therapy tometformin in patientswith Type 2 diabetes, based
on the results of clinical trial conducted in Asian population. METHODS: The val-
idated UKPDS Outcomes Model was used to project life expectancy, quality ad-
justed life years (QALYs), incidence of diabetes-related complication and cost of
complications in patients receiving those regimens. Baseline cohort characteristics
and treatment effects were derived from an Asian study. China-specific complica-
tion costs and utility scoreswere taken from local studies. Patients’ outcomeswere
modelled for 30 years and incremental cost-effectiveness ratios (ICERs) were cal-
culated for liraglutide compared with glimepiride from the health care system
perspective. Both costs and clinical benefits were discounted at 3%. Sensitivity
analyses were also performed. RESULTS: Over a period of 30 years, compared with
glimepiride, liraglutide 1.8mg was associated with improvements in life expec-
tancy (0.1 year) and QALY (0.168), and a reduced incidence of diabetes-related
complications leading to an ICER per QALY gained of CNY 256871. Sensitivity anal-
yses indicated that the final ICER was highly sensitive to time horizon, price of
liraglutide and the effects of liraglutide in improving the systolic blood pressure
and lipid profiles but insensitive to the effect of liraglutide in the reduction in
HbA1c. CONCLUSIONS: Long-term projections indicated that liraglutide was asso-
ciated with increased life expectancy, QALYs, and reduced incidences of compli-
cation comparing with glimepiride. If the 3X per capita GDP was adopted as the
WTP threshold per QALY, however, the administration of liraglutide was not con-
sidered cost-effective in China, and less likely to be cost effective in most Asian
developing economies (e.g., Thailand, Malaysia) than Asian developed economies
(Japan, Singapore). But with a 38% reduction of our modelled acquisition cost of
liraglutide (from CNY369.2 - CNY 228.02), liraglutide could be considered cost-ef-
fective in China.
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